Bristol Myers Squibb's Zeposia launches into crowded MS market

When Bristol Myers Squibb nabbed Celgene's long-sought FDA nod for multiple sclerosis drug Zeposia, the COVID-19 pandemic was in full swing—not the ideal time for a launch. Now, the company thinks the time has come.